Healthcare Global Enterprises Ltd
Healthcare Global Enterprises Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase. Expectation of strong year-on-year growth in both top line and bottom line for the next financial year (FY26), as stated by Raj Gore.
From Healthcare Global Enterprises Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase.
- Established centers are expected to grow at 13-14% going forward, outpacing the market growth rate of around 11%.
- Emerging centers show exceptional performance, with 25% revenue growth in Q3 and expected continued strong growth.
- New centers in Bangalore (brownfield expansions) will initially generate operating losses but are expected to be operationalized by FY '26.
- The company plans to focus on organic plus brownfield growth primarily, with potential inorganic growth (mergers/acquisitions) to be considered in due course.
2 more points from Healthcare Global Enterprises Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current and near-term capex guidance is INR 275–280 crores per annum for FY '25 and FY '26.
- Of this, approximately INR 100 crores annually is maintenance capex.
- Growth capex related to new centers and expansions is expected to be largely completed by FY '26.
- Post FY '26, capex will normalize to around INR 100 crores per annum (maintenance), with some inflation.
- Strategic investments include operationalizing two new brownfield centers in Bangalore in FY '26.
- Focus on hub-and-spoke model infusion clinics and new centers in Bangalore for growth.
2 more points from Healthcare Global Enterprises Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Healthcare Global Enterprises Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹652 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Healthcare Global Enterprises Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Healthcare Global Enterprises Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Healthcare Global Enterprises Ltd Q3 FY25 results?
Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase. Expectation of strong year-on-year growth in both top line and bottom line for the next financial year (FY26), as stated by Raj Gore.
What is Healthcare Global Enterprises Ltd share price analysis?
Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.
Is Healthcare Global Enterprises Ltd planning capital expenditure?
Current and near-term capex guidance is INR 275–280 crores per annum for FY '25 and FY '26.
Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.